ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
![](https://agendia.com/wp-content/uploads/2020/11/subnav-bigimage4-3.png)
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
MammaPrint® Approved for Reimbursement in Germany
IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today that the Federal Joint Committee (G-BA) has approved MammaPrint® , Agendia's 70-Gene Breast Cancer Recurrence Assay. The G-BA Read More
Agendia to Participate in Stifel 2020 Virtual Healthcare Conference
Irvine, Calif., October 15, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020. Agendia Read More
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany
IRVINE, CALIF., U.S – 6 October 2020 – Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Read More
Agendia Celebrates Breast Cancer Awareness Month with Digital Art Installation
I AM HERE: An Intimate Portrait Series launches today Irvine, Calif., October 1, 2020 – In celebration of Breast Cancer Awareness Month, Agendia, Inc., a world leader in precision oncology for breast cancer, is proud Read More